COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS
Annually, all over the world there are 300 000 new patients with leukemia (approximately 3% of all oncology diseases), and mortality due to leukemia is 220 000 patients. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of pa...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2015-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
Call Number: |
A1234.567 |
---|---|
Copy 1 | Available |